Watch: Going Beyond the Script of ‘Dopesick’ and America’s Real-Life Opioid Crisis
KHN teamed up with Hulu for a discussion of America's opioid crisis, following the Oct. 13 premiere of the online streaming service’s new series “Dopesick.”
Drugs
461-480 of 1,313 results
-
-
The Public Backs Medicare Rx Price Negotiation Even After Hearing Both Sides’ Views
But Americans generally have little confidence that the White House or Congress will recommend the right thing, a new poll shows.
-
What the Stalemate on Capitol Hill Means for Your Drug Prices
Despite big 2020 campaign promises to deliver lower costs on prescription drugs, Democrats have failed to unite around a legislative plan.
-
Alzheimer’s Drug Targets People With Mild Cognitive Impairment. What Does That Mean?
The condition can be an early signal of Alzheimer’s disease, but not always. Other health concerns could be causing thinking or memory problems, and the new drug, Aduhelm, would not be appropriate for those patients.
-
From the FDA’s Empty Seat to Chock-Full ICUs, Journalists Recap the Week’s Stories
KHN and California Healthline staff made the rounds on national and local media this week to discuss their stories. Here’s a collection of their appearances.
-
A Daily Pill to Treat Covid Could Be Just Months Away, Scientists Say
At least three promising antiviral treatments for covid-19 are being tested in clinical trials, with results expected as soon as late fall or winter.
-
KHN’s ‘What the Health?’: The Autumn of Democrats’ Discontent
Congress is back in session with a short time to finish a long to-do list, including keeping the government operating and paying its bills. Hanging in the balance is President Joe Biden’s entire domestic agenda, including major changes proposed for Medicare, Medicaid and the Affordable Care Act. Meanwhile, the new Texas abortion law that bans the procedure early in pregnancy is prompting action in Washington. Joanne Kenen of Politico, Mary Ellen McIntire of CQ Roll Call and Sarah Karlin-Smith of the Pink Sheet join KHN’s Julie Rovner to discuss these issues and more. Also, Rovner interviews former FDA Commissioner Scott Gottlieb about his new book on the covid-19 pandemic.
-
Biosimilar Drugs Are Cheaper Than Biologics. Are They Similar Enough to Switch?
Biologic drugs, made from living organisms, and the cheaper biosimilar drugs that mimic them are more complex than chemical drugs and their generic counterparts. The Food and Drug Administration says biosimilars are as safe and effective as the biologics, and doctors agree — but they are cautious about changing the treatment regimen of patients doing well.
-
Public Health Experts ‘Flabbergasted’ That Biden Still Hasn’t Picked an FDA Chief
The Food and Drug Administration has been mired in controversies related to drug approvals and covid vaccines, all without a permanent leader.
-
Congress Cites KHN Investigation in Probe of National Academies
The House oversight committee is requesting conflict-of-interest disclosure forms from a National Academies committee studying organ transplants. KHN previously reported on apparent conflicts among members of a committee studying drug waste.
By Christina Jewett and JoNel Aleccia -
KHN’s ‘What the Health?’: Much Ado About Drug Prices
Democrats have hit a snag in their effort to compile a $3.5 trillion social-spending bill this fall — moderates are resisting support for Medicare drug price negotiation provisions that would pay for many of the measure’s health benefit improvements. Meanwhile, the new abortion restrictions in Texas have moved the divisive issue back to the political front burner. Alice Miranda Ollstein of Politico, Rachel Cohrs of Stat and Shefali Luthra of The 19th join KHN’s Julie Rovner to discuss these issues and more. Also this week, Rovner interview’s KHN’s Phil Galewitz about the latest KHN-NPR “Bill of the Month” installment, about two similar jaw surgeries with very different price tags.
-
From Uber Rides to Patient Advocates: What It Takes to Increase ER Addiction Treatment
Despite widespread consensus on the importance of addiction treatment in the ER, many hospitals fail to screen for substance use, offer medications to treat opioid use disorder or connect patients to follow-up care. But some are working to change that.
-
These Governors Push Experimental Antibody Therapy — But Shun Vaccine and Mask Mandates
Governors in Southern states, amid a surge of delta-variant infections, are rushing to provide an experimental antibody cocktail therapy, even as they oppose measures like mask mandates and vaccine passports that health officials say can prevent infection in the first place.
-
‘We Sent a Terrible Message’: Scientists Say Biden Jumped the Gun With Vaccine Booster Plan
Many experts say the evidence doesn’t justify widespread booster shots for adults.
-
KHN’s ‘What the Health?’: Booster Time
As the delta variant continues to spread around the U.S., the Biden administration is taking steps to authorize covid vaccine boosters, require nursing home workers to be vaccinated and protect school officials who want to require masks despite state laws banning those mandates. Meanwhile, the U.S. House is returning from its summer break early to start work on its giant budget bill, which includes a long list of health policy changes. Alice Miranda Ollstein of Politico, Margot Sanger-Katz of The New York Times and Kimberly Leonard of Business Insider join KHN’s Julie Rovner to discuss these issues and more.
-
The White House Says Boosters for All. Here’s What You Need to Know.
Federal officials are preparing to offer those who received Pfizer or Moderna covid vaccines a third dose in September. But the FDA and CDC are still reviewing the data for final clearance.
-
Have Vaccines, Will Travel: On the Road With a Covid Entrepreneur
While many businesses scaled back at the height of the pandemic, one Montana man used covid-19 to open his own mobile pharmacy. He’s now bringing covid shots to Montana’s vaccine deserts while filling his wallet. But he cannot fill all the vaccination gaps.
-
Pfizer CEO to Public: Just Trust Us on the Covid Booster
As pharmaceutical companies declare a need for boosters, scientists and doctors emphasize there’s no proof yet.
-
KHN’s ‘What the Health?’: The Senate Acts
The U.S. Senate worked well into its scheduled August recess to pass a bipartisan infrastructure bill and a budget blueprint that outlines a much larger bill — covering key health priorities — to be written this fall. Meanwhile, the latest surge of covid is making both employers and schools rethink their opening plans. Joanne Kenen of Politico, Mary Ellen McIntire of CQ Roll Call and Yasmeen Abutaleb of The Washington Post join KHN’s Julie Rovner to discuss these issues and more. Also, for “extra credit,” the panelists suggest their favorite health policy stories of the week they think you should read, too.
-
National Academies’ Report Took Pharma-Friendly Stance After Millions in Gifts From Drugmakers
Congress tapped a national academies committee to examine a drug cost issue. It got a report that includes “egregious” failures to disclose conflicts of interest.